Guardant Health, Inc.
Guardant Health, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding sales/marketing. - Full-year 2026 revenue guidance raised to $1.30 - $1.32 billion, representing 32% to 34% growth. - Oncology revenue expected to grow 28% to 29% with volume growth greater than 35%. - Screening revenue expected between $186 million and $198 million, driven by Shield volume of approx.
From Guardant Health, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding sales/marketing.
- Expect continued hiring of high-quality reps despite competitive field; no pipe-by-pipe sales force updates due to commercial sensitivity.
- Shield volumes showing strong acceleration, driven by DTC campaigns, EMR connectivity, and recent Quest partnership.
- Guardant360 Liquid expects sustained 20%-30%+ volume growth aided by Smart platform innovation and upcoming FDA approvals.
- Reveal product volumes grew over 100% YoY; strong growth expected in CRC, breast, lung cancers, plus therapy monitoring.
- Future revenue and volume growth expected from MolDx reimbursement approvals, commercial expansion, and new clinical applications.
- ASP for Shield stable around $775-$800, with upward potential as Medicare coverage expands.
2 more points from Guardant Health, Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Guardant Health, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Continued investment in building out the screening sales infrastructure to support Shield and oncology revenue growth (Page 6, 11).
- Advancing CDx (companion diagnostics) programs and expanding strategic partnerships with leading biopharma companies (Page 6).
- Scaling the InfinityAI platform to enhance AI capabilities and actionable insights using large datasets (Page 10).
- Investing in marketing campaigns including DTC (direct-to-consumer) and HCP (healthcare provider) campaigns to drive demand, with reinvestment of incremental gross profit from screening into commercial expansion (Page 11, 13).
- Ongoing investments in lab workflow efficiencies and automation expected to reduce Shield cost per test further in 2027 (Page 5).
2 more points from Guardant Health, Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Guardant Health, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Guardant Health, Inc. said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Quest Diagnostics Incorporated (Q2 FY26)
Quest Diagnostics Incorporated Q2 FY26 quarterly results analysis. Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. Market
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Guardant Health, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Guardant Health, Inc. Q2 FY26 results?
- Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding sales/marketing. - Full-year 2026 revenue guidance raised to $1.30 - $1.32 billion, representing 32% to 34% growth. - Oncology revenue expected to grow 28% to 29% with volume growth greater than 35%. - Screening revenue expected between $186 million and $198 million, driven by Shield volume of approx.
What is Guardant Health, Inc. share price analysis?
Guardant Health, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -208.7 with a market cap of $17,665. Investors should review the full earnings analysis for detailed insights.
Is Guardant Health, Inc. planning capital expenditure?
- Continued investment in building out the screening sales infrastructure to support Shield and oncology revenue growth (Page 6, 11).
Keep Guardant Health, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.